2021
Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic
Cadamuro M, Lasagni A, Lamarca A, Fouassier L, Guido M, Sarcognato S, Gringeri E, Cillo U, Strazzabosco M, Marin JJ, Banales JM, Fabris L. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opinion On Investigational Drugs 2021, 30: 377-388. PMID: 33622120, PMCID: PMC8194059, DOI: 10.1080/13543784.2021.1880564.Peer-Reviewed Original ResearchConceptsExtrahepatic CCAMinority of patientsComplex molecular landscapePro-oncogenic pathwaysSystematic literature searchDeep phenotyping studyOutcome predictorsExtrahepatic cholangiocarcinomaOverlooked diseaseActionable driversClinical developmentActionable targetsMolecular alterationsOncogenic driversTumor microenvironmentHeterogeneous tumorsLiterature searchDistinct entityMolecular profilingSpecific alterationsMolecular landscapePrecision medicinePerturbed pathwaysImmunotherapyPhenotyping studies
2019
Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances
Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wang X, Zhu AX. Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances. Hepatology 2019, 69: 1803-1815. PMID: 30251463, PMCID: PMC6433548, DOI: 10.1002/hep.30289.Peer-Reviewed Original ResearchConceptsIntrahepatic cholangiocarcinomaMortality rateFuture translational research opportunitiesNonalcoholic fatty liver diseasePlatelet-derived growth factor DPrimary hepatobiliary cancerFatty liver diseaseRecent clinical trialsTranslational research findingsHigh mortality rateCancer-associated myofibroblastsTranslational research opportunitiesGrowth factor DNonspecific cirrhosisLiver diseaseHepatobiliary cancersSerum biomarkersRisk factorsClinical trialsExtracellular vesicle biomarkersLiver cancerMedical conditionsAggressive cancerIntrahepatic cholangiocarcinogenesisTherapeutic implications